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Brucella abortus 2308 derivatives with mini-Tn5 insertions in purE, purL, and purD display significant
attenuation in the BALB/c mouse model, while isogenic mutants with mini-Tn5 insertions in pheA, trpB, and
dagA display little or no attenuation in cultured murine macrophages or mice. These experimental findings
confirm the importance of the purine biosynthesis pathways for the survival and replication of the brucellae
in host macrophages. In contrast to previous reports, however, these results indicate that exogenous trypto-
phan and phenylalanine are available for use by the brucellae in the phagosomal compartment.
Brucella abortus is a facultative, gram-negative pathogen of
humans and animals that inhabits macrophages (2). The ca-
pacity to withstand nutritional deprivation would be expected
to be particularly important for the survival of B. abortus, since
this organism does not escape from the phagosome into the
nutrient-rich environment of the host cell cytoplasm (2). In-
deed, previous studies suggest that the brucellae encounter a
considerable degree of nutritional deprivation during their
long-term residence in host macrophages. Brucella melitensis
purE (5) and Brucella suis aroC (12) mutants, for example, are
unable to maintain chronic infection in experimentally infected
mice, and the attenuation of the B. melitensis purE mutant
purE201 extends to the natural ruminant host (4) and nonhu-
man primates (M. Nikolich, personal communication). These
observations are also consistent with those seen with auxotro-
phic mutants of Salmonella and Mycobacterium and indicate
that the availability of certain nutrients is severely restricted in
the phagosomal compartment of host macrophages (3, 11, 22).
In an effort to gain a better understanding of the metabolic
versatility required for sustained intracellular residence by the
brucellae in host macrophages, transposon mutagenesis and an
in vitro screen were employed to identify B. abortus 2308 de-
rivatives with mini-Tn5 insertions in genes required for resis-
tance to nutrient deprivation. Transposon mutagenesis of this
strain was performed by conjugative transfer of the mini-Tn5
derivative Km1 by employing pUT as the delivery vector and
Escherichia coli S17-1pir as the conjugal donor strain (6, 14,
28). Approximately 1,000 B. abortus mini-Tn5 mutants were
patched with sterile toothpicks onto Schaedler agar supple-
mented with 5% defibrinated bovine blood (SBA), SBA sup-
plemented with 45 g of kanamycin/ml (SBAk), and Ger-
hardt’s minimal medium (13) supplemented with 1.5% agar
(GMMA). Plates were incubated at 37°C with 5% CO2 and
examined for growth after 4, 7, and 10 days of incubation.
Schaedler agar, the basal medium for SBA, is a complex cul-
ture medium containing enzymatic digests of casein, animal
and plant tissues, yeast extract, glucose, cystine, and hemin
(Difco manual, 10th ed., Difco Laboratories, Detroit, Mich.).
In contrast, GMM, the base for GMMA, is a defined medium
formulated during a study aimed at defining the minimal in
vitro growth requirements of Brucella strains (13). GMM con-
tains glycerol and lactate as carbon and energy sources. SBA
and SBAk support luxuriant growth of B. abortus 2308 and
2308 carrying the plasmid pBBR1MCS2 (which confers kana-
mycin resistance) (19), respectively, with individual colonies
being clearly visible after 48 h of incubation. The formation of
visible colonies by 2308 on GMMA, on the other hand, re-
quires 96 h or more of incubation. Thus, for the purposes of
the study described in this report, SBA was considered to be a
nutritionally complete growth medium and GMMA was con-
sidered a nutritionally restricted growth medium for the bru-
cellae. Following incubation on GMMA and SBAk, 44 of the
mini-Tn5 mutants displayed defective growth or no growth on
GMMA but grew on SBAk as well as 2308(pBBR1MCS2). To
eliminate the lack of standardization in inoculum size associ-
ated with patching the brucellae onto the growth medium with
sterile toothpicks, the 44 B. abortus mini-Tn5 mutants that
displayed defective growth on GMMA were inoculated into 1
ml of brucella broth supplemented with 45 g of kanamycin/ml
and incubated with shaking in a 37°C water bath. After 48 h of
incubation, the bacterial cells were harvested by centrifugation,
washed once with 1 ml of sterile phosphate-buffered saline,
and resuspended to an optical density at 600 nm of 0.15 (ap-
proximately 109 CFU/ml). The resulting bacterial suspensions
were diluted to a final cell concentration of 105 CFU/ml in
sterile phosphate-buffered saline, 100 l of each cell suspen-
sion was plated onto SBAk and GMMA supplemented with 45
g of kanamycin/ml, and the plates were incubated at 37°C
with 5% CO2. Following 4, 7, and 10 days of incubation, growth
on these plates was examined and compared with the growth
displayed by B. abortus 2308(pBBR1MCS2) on these two
growth media. Following this second screen for defects in
growth on the nutritionally deficient medium, 12 of the 44
mini-Tn5 mutants displayed defective or no growth on GMMA
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but growth comparable to that of the parental 2308 strain on
SBA.
Southern blot analysis (27) with probes specific for the kana-
mycin resistance gene in the mini-Tn5 derivative Km1 and the
ampicillin resistance gene in pUT was used to confirm that the
transposon had inserted into a single genetic locus in each of
these mutants. To clone the mini-Tn5-disrupted genes, geno-
mic DNA from the mutants was digested with either EcoRI
or NcoI, yielding fragments containing the mini-Tn5 and
flanking B. abortus genomic sequences and cloned into ei-
ther the EcoRI site of pBluescript II KS() or the NcoI site
of pGEM5Zf. The resulting recombinant plasmids were used
to transform E. coli DH5 cells, and transformants containing
plasmids carrying the mini-Tn5-disrupted genes were selected
by plating on Luria-Bertani medium supplemented with kana-
mycin and ampicillin. The nucleotide sequences of the mini-
Tn5-disrupted genes cloned in these plasmids were determined
using the dideoxy-based methods described by Sanger et al.
(30). Brucella-specific DNA sequences identified in this fashion
were compared against those in the B. melitensis 16M genome
sequence (7) by using the tblastx algorithm. The strain desig-
nations for these mutants along with the identity of the mini-
Tn5-disrupted loci in these strains are presented in Table 1.
Four of the B. abortus mutants identified in this genetic
screen had mini-Tn5 insertions in genetic loci involved in pu-
rine metabolism (36) and, as expected, B. abortus AR54 (purL::
miniTn5) and AR975 (purE::miniTn5) both displayed purine
auxotrophy in vitro. Neither strain would grow in GMM or on
GMMA unless the medium was supplemented with 5 mM ade-
nine and 0.3 mM guanine. All three of the B. abortus deriva-
tives with mini-Tn5 insertions in purine biosynthesis genes also
displayed significant attenuation in cultured murine macro-
phages (Fig. 1) and in experimentally infected mice (Fig. 2). A
previously described directed reversion strategy (21) was used
to replace the mini-Tn5-disrupted purL and purE loci in AR54
and AR975, respectively, with the corresponding wild-type
purL and purE genes. The resulting revertants, AR54R and
AR975R, grew as well as 2308 on GMMA without adenine or
guanine supplementation and also displayed wild-type viru-
lence in cultured murine macrophages (Fig. 1 and data not
shown) and in experimentally infected BALB/c mice (Fig. 2).
Thus, the results of the study presented here support and
extend those reported previously for B. melitensis (5, 8) and
B. suis (17) and indicate that the brucellae require intact pu-
rine biosynthesis pathways in order to maintain long-term sur-
vival in the phagosome. These experimental findings also agree
with those observed with other intracellular bacteria that re-
main confined to the phagosomal compartment, such as Sal-
monella enterica serovar Typhimurium (20, 32) and the Myco-
bacterium spp. (16), and suggest that exogenous purine pools
are limiting in this intracellular environment.
Of those B. abortus mutants with mini-Tn5 insertions in
genes predicted to be involved in amino acid biosynthesis and
transport, only the ilvD mutant, AR943, displayed attenuation
in both macrophages (Fig. 3) and mice (Fig. 4). The remaining
amino acid biosynthesis mutants [AR93 (trpB::miniTn5) and
AR408 (pheA::miniTn5)] displayed wild-type virulence in mice.
The ilvD gene product, dihydroxy acid dehydratase, partici-
pates in the biosynthesis of all three of the branched chain
amino acids, leucine, isoleucine, and valine (34) and, as ex-
pected, the B. abortus ilvD mutant AR943 displays auxotrophy
for all three of these amino acids when cultured on GMMA. In
contrast, the products of the trpB and pheA genes are specifi-
cally dedicated to the biosynthesis of tryptophan and phenyl-
alanine, respectively (24), and the B. abortus trpB and pheA
mutants display auxotrophy only for the corresponding single
amino acid when cultivated on GMMA. Consequently, our
experimental findings with the B. abortus ilvD, trpB, and pheA
mutants suggest that tryptophan and phenylalanine are avail-
able to the brucellae in their intracellular niche but that other
amino acids (e.g., leucine, isoleucine, or valine) are not. The E.
coli dagA gene (also known as cycA) encodes a glycine, alanine,
and serine transporter (25). The slight attenuation displayed by
the B. abortus dagA mutant AR536 in experimentally infected
mice suggests that the transport of these particular amino acids
by the brucellae may be important at some stage during the
infectious process. The modest and transient nature of the
attenuation displayed by AR536 in mice, however, coupled
with the failure of this mutant to display a phenotype in cul-
tured murine macrophages, makes it impossible to make de-
finitive conclusions regarding the availability of glycine, ala-
nine, or serine in the phagosomal compartment. Indeed, an
analysis of the virulence profiles of isogenic B. abortus mutants
with genetic lesions specifically affecting the biosynthesis of
each of these individual amino acids would be more informa-
tive in this regard.
The results of earlier studies with a B. suis aroC mutant,
which cannot produce a wide variety of aromatic compounds,
including the amino acids tryptophan and phenylalanine (12),
and B. suis mutants with mini-Tn5 insertions in a variety of
amino acid biosynthesis loci (17) suggested that a variety of
amino acids, including leucine, glycine, and serine, are not
available to B. suis 1330 in its intracellular niche. It is impor-
tant to note in this regard, however, that the basis for the
attenuation of the B. suis aroC mutant in the mouse model in
these earlier studies could well have been its inability to pro-
duce other aromatic compounds rather than its auxotrophy for
tryptophan and phenylalanine. In this same vein, the B. suis
mutants with mini-Tn5 insertions in amino acid biosynthesis
genes were identified in these earlier studies based on their
attenuation in the human monocytic cell line THP-1, but these
strains were not evaluated in the mouse model. Whether the
TABLE 1. Identity of the mini-Tn5-disrupted loci in B. abortus









AR54 purL Purine biosynthesis BMEI1124
AR86 rplS 50S ribosomal subunit L19 BMEI0156
AR93 trpB Tryptophan biosynthesis BMEI2018
AR408 pheA Phenylalanine biosynthesis BMEI1905
AR416 fatD Ferric siderophore transport BMEII0606
AR423 bvrS Two-component response regulator BMEI2034
AR425 eryC Erythritol catabolism BMEII0428
AR536 dagA Glycine, alanine, and serine transport BMEII0783
AR609 purSL Purine biosynthesis BMEI1123
AR875 purH Purine biosynthesis BMEI0233
AR943 ilvD Branched-chain amino acid biosynthesis BMEI1848
AR975 purE Purine biosynthesis BMEI0296
a Open reading frame designation in the B. melitensis genome.
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differential behavior of the B. abortus and B. suis amino acid
biosynthesis mutants in cultured phagocytes reflects differ-
ences between the bacterial host strains being examined or
differences in nutrient availability between the phagosomal
compartments of murine and human phagocytes is presently
unknown. Nevertheless, the disparate nature of these findings
indicates that a more thorough investigation of the in vivo
phenotypes of Brucella amino acid auxotrophs will be neces-
sary before we have an accurate picture of the availability of
these compounds to the brucellae during their long-term
FIG. 1. Intracellular survival and replication of B. abortus strains 2308 (F), AR54 (2308 purL::miniTn5) (), AR875 (2308 purH::miniTn5) (Œ),
and AR975 (2308 purE::miniTn5) () (A) and of B. abortus 2308, AR975 (2308 purE::miniTn5), and AR975R (AR975 purE::miniTn53purE)
(B) in cultured resident peritoneal macrophages from BALB/c mice. Macrophages were isolated and plated at a density of 5  105 cells per well
in 96-well microtiter plates and infected with brucellae opsonized with hyperimmune murine serum at a multiplicity of infection of 100:1, using the
methods described by Elzer et al. (10). Results are expressed as percent survival, which was calculated by dividing the number of intracellular brucellae
present at a particular sampling time by the number of intracellular brucellae present immediately after phagocytosis (t  0). *, P  0.05; , P 
0.01 for comparisons of 2308 versus AR54, AR875, or AR975. †, P  0.05 for comparisons of AR975R versus AR975 by using the Student t test
(26).
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residence in the phagosomal compartment of host macro-
phages.
The remaining B. abortus mutants isolated in our genetic
screen had mini-Tn5 insertions in genes predicted to be in-
volved in translation (rplS [23]), erythritol catabolism (eryC
[29]), iron acquisition (fatD [18]), and the maintenance of cell
envelope integrity (bvrS [33]). Since the phenotypes of B. abor-
tus ery and bvrS mutants have been described previously and an
evaluation of the contribution of the fat locus to iron acquisi-
tion in B. abortus is the subject of a separate study in our
laboratory, the B. abortus mini-Tn5 mutants AR425 (eryC),
AR423 (bvrS), and AR416 (fatD) were not further character-
FIG. 2. Spleen colonization profiles of B. abortus strains 2308 (F), AR54 (2308 purL::miniTn5) (), AR875 (2308 purH::miniTn5) (), and
AR975 (2308 purE::miniTn5) (Œ) (A) and B. abortus 2308 (F), AR54 (2308 purL::miniTn5) (Œ), AR54R (AR54 purL::miniTn53purL) (}),
AR975 (2308 purE::miniTn5) (), and AR975R (AR975 purE::miniTn53purE) () (B) in experimentally infected BALB/c mice. Brucella strains
were grown on SBA or SBAk, and infection doses were prepared as described elsewhere (9). Seven- to 9-week-old female BALB/c mice were
infected with 5  104 (A) or 2  104 (B) CFU of brucellae via the intraperitoneal route. At 1, 4, 8, and 12 weeks postinfection, three to five mice
from each experimental challenge group were sacrificed by isoflurane overdose, their spleens were removed and homogenized, and the total
number of brucellae per spleen was determined by serial dilution and plating onto SBA and/or SBAk. Results are expressed as total CFU per
spleen  the standard deviation. , P  0.05; , P  0.01 for comparisons of 2308 versus AR54, AR875, or AR975. †, P  0.05 for comparisons
of AR54R versus AR54; ‡‡, P  0.01 for comparisons of AR975R versus AR975 (Student’s t test [26]).
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ized during the course of this study. Similarly, the B. abortus
mini-Tn5 mutant AR86 was excluded from this study because
the rplS mutation would be expected to have a detrimental
effect on ribosome assembly (23) and the resulting defect in
translational efficiency would make the results of in vivo stud-
ies with this mutant difficult, if not impossible, to interpret.
The experimental findings presented in this report provide
us with a better understanding of the nutritional environment
within which the brucellae reside in the phagosomal compart-
ment of host macrophages and the ways in which they adapt to
this niche. They may also have important implications with
regard to vaccine development and chemotherapy. Although
no safe and effective vaccine for human brucellosis currently
exists, an attenuated B. melitensis purE mutant has been exten-
sively studied in a variety of experimental hosts (4, 5, 15),
including nonhuman primates (M. Nikolich, personal commu-
nication) and appears to be an excellent candidate in this
regard. If B. melitensis purH and purL mutants show similar
differences in their attenuation in nonhuman primates as their
B. abortus counterparts do in the mouse model, it may be
possible to exploit this relationship to improve upon the B.
melitensis purE-based vaccine candidate. This will be particu-
larly important if the B. melitensis purE mutant fails to display
the balance of attenuation and immunogenicity required of
human vaccines. Purine analogs have also been evaluated as
potential chemotherapeutic agents against Mycobacterium tu-
berculosis (1, 31). Based on the critical nature of de novo
purine biosynthesis for the successful survival of the brucellae
FIG. 3. Intracellular survival and replication of B. abortus strains 2308 (F), AR93 (2308 trpB::miniTn5) (), AR408 (2308 pheA::miniTn5) (}),
AR536 (2308 dagA::miniTn5) (Œ), and AR943 (2308 ilvD::miniTn5) () in cultured murine resident peritoneal macrophages. Macrophages were
isolated and plated at a density of 5  105 cells per well in 96-well microtiter plates and infected with brucellae opsonized with hyperimmune
murine serum at a multiplicity of infection of 100:1 using the methods described by Elzer et al. (10). Results are expressed as percent survival, which
was calculated by dividing the number of intracellular brucellae present at a particular sampling time by the number of intracellular brucellae
present immediately after phagocytosis (t  0). **, P  0.01 for comparisons of 2308 versus AR943 by using the Student t test (26).
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in their intracellular niche, these purine analogs may be effec-
tive as brucellacidal agents in vivo. Such a finding would be
particularly important with regard to the treatment of human
brucellosis, since this disease is notoriously difficult to cure
with the currently used chemotherapeutic regimens (35).
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